Introduction
Nitric oxide (NO) is a free radical, produced from L-arginine and molecular oxygen by NO synthases (NOS). Two isoforms of NOS are constitutively expressed in neurons and endothelial cells and are termed nNOS (NOS 1) and eNOS (NOS 3), respectively. These isoforms are calcium-dependent and produce low levels of NO for short periods in response to physiological stimuli. A third isoform of NOS, called inducible NOS (iNOS or NOS 2) is calcium-independent and is not constitutively expressed but requires cytokines or endotoxins for induction of its expression. Once expressed, iNOS produces large amounts of NO for prolonged periods of time that exerts cytotoxic and cytostatic effects and has been implicated in diverse functions associated with inflammation and injury. 1, 2 The high output of NO favours the reaction between NO and the superoxide anion to form peroxynitrite. The latter is a strong oxidant that can nitrate phenolic rings of tyrosine residues of proteins, leading to the formation of nitrotyrosine, which is easily detected with nitrotyrosine antibodies. 3 The mechanisms by which diabetes induces retinopathy and blindness are not yet clear. However, some evidences suggest that an increased production of NO is involved in that process. In fact, we have observed substantial iNOS immunoreactivity in the retinas from human subjects with diabetes and nonproliferative diabetic retinopathy. 4 In addition, increased expression of iNOS immunoreactivity and NO production in retinas from diabetic rats were reported. 5, 6 Several studies provided evidence implicating NO in blood-brain barrier breakdown 7, 8 and blood-retinal barrier breakdown. 5 Moreover, NO has been implicated as a mediator of angiogenesis. In vitro and in vivo studies have shown that NO stimulates endothelial cell migration, proliferation, and differentiation into capillaries. 9, 10 One possible mechanism might involve the upregulation of a V b 3 integrin on endothelial cells, a critical mediator of cell-matrix adhesion and migration. 10 Vascular endothelial growth factor (VEGF)/vascular permeability factor (VPF) is an endothelial cell-specific mitogen 11 and strongly induces both physiological and pathological angiogenesis. 12 VEGF is implicated strongly in the development of retinal and iris neovascularization in proliferative diabetic retinopathy. Eyes with nonproliferative and proliferative diabetic retinopathy showed an upregulated expression of VEGF and its mRNA by the retina. 13, 14 Several studies demonstrated that NO plays a critical role in VEGF-induced vascular hyperpermeability [15] [16] [17] [18] and angiogenesis. [19] [20] [21] [22] Furthermore, VEGF has been shown to induce the expression of iNOS 23 and stimulate production of NO. 18, 24, 25 The retina contains two types of macroglial cells. The most abundant are the Mü ller cells, which project from the retinal ganglion cell layer to the photoreceptors, whereas the astrocytes, which originate in the optic nerve and migrate into the retina during development, 26 reside as a single layer adjacent to the inner limiting membrane. Glial cells provide structural and metabolic support for retinal neurons and blood vessels, and the cells become reactive in certain injury states. [27] [28] [29] Several studies suggested that glial reactivity and altered glial metabolism are early pathological events in the retina during diabetes. [30] [31] [32] [33] The most constant manifestation of reactivity is the increase in immunoreactivity for the intermediate filament protein glial fibrillary acidic protein (GFAP). 30 As NO has been shown to act as a crucial signal in the response of VEGF and as VEGF stimulates production of NO, we hypothesized that VEGF and iNOS are coexpressed in the retinas of human subjects with diabetes. To test our hypothesis, we used immunohistochemical techniques to study the distribution of VEGF and iNOS in the retinas from diabetic patients. In addition, we examined the expression of nitrotyrosine, a measure of in situ peroxynitrite modification of proteins. Furthermore, the expression of GFAP was compared in the retinas from diabetic patients and nondiabetic individuals.
Methods
We obtained eight human post-mortem eyes from four consecutive subjects with diabetes mellitus. No subject had a history of retinal photocoagulation. Nonproliferative diabetic retinopathy was documented to be present in two cases (Cases 1 and 2). The status of the retina was unknown in two cases (Cases 3 and 4). We also obtained eight eyes from four persons with no history of diabetes or of ocular disease as determined by gross pathologic examination. Immediately after the specimens arrived in the laboratory, an incision was made 3 mm posterior to the limbus, and the cornea, iris, lens, and vitreous were gently removed. The retina and uveal tissue were dissected free of surrounding tissue and divided into two parts. One part was fixed in 4% paraformaldehyde and embedded in paraffin and the other part was immediately snap-frozen in optimum cutting temperature compound (Tissue-Tek; Miles Laboratories, Elkhart, IN, USA) and maintained at À801C until use.
Immunohistochemical techniques were used. After deparaffinization, endogenous peroxidase was abolished with 2% hydrogen peroxide in methanol for 3 min and nonspecific background staining was blocked by incubating the sections for 7 min in normal swine serum. Subsequently, sections were stained using a three-step avidin-biotin complex. Three sections were stained per antibody for each eye. For iNOS detection, the sections underwent heat-induced antigen retrieval with a microwave oven (three cycles of 5 min at 650 W). Subsequently they were incubated overnight with rabbit polyclonal anti-iNOS antibody (Transduction Laboratories, Lexington, KY, USA) diluted 1 : 100. The slides for VEGF detection were incubated for 30 min with rabbit polyclonal anti-VEGF antibody (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) diluted 1 : 100. The slides for GFAP detection were incubated for 30 min with rabbit polyclonal anti-GFAP antibody (DAKO, Glostrup, Denmark) diluted 1 : 300. For the expression of nitrotyrosine, frozen sections were cut, dried overnight at room temperature, fixed in acetone for 10 min and incubated for 30 min with mouse monoclonal antinitrotyrosine (Cayman, Ann Arbor, MI, USA) diluted 1 : 50.
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Incubation of primary antibodies was followed by incubation with the biotinylated secondary antibody and reacted with the avidin-biotinylated peroxidase complex. Secondary and tertiary reagents were purchased from DAKO (Denmark). All incubations were carried out for 30 min at room temperature and followed by three washes in phosphate-buffered saline (PBS), pH 7.2. The reaction product was visualized by incubation for 10 min in 0.05 mol/1 acetate buffer at pH 4.9, containing 3-amino-9-ethyl-carbazole 0.05% (AEC, Sigma-Aldrich, Bornem, Belgium) and hydrogen peroxide 0.01%, resulting in bright-red immunoreactive sites. The slides were faintly counterstained with Mayer's haematoxylin. Finally, the sections were rinsed with distilled water and coverslipped with glycerol. Control slides were treated in an identical manner, except that an irrelevant antibody was used in the first step or the primary antibody was omitted. Evaluation of the retinas was performed by two independent observers (AMA and KG). One of them (KG) was unaware of the origin of the specimens.
Results
Donor age and sex, type of diabetes, duration of diabetes, cause of death, and death to enucleation time are summarized in Table 1 . In retinas from all subjects without diabetes, weak immunoreactivity for GFAP was noted very close to internal limiting membrane in nerve fibre layer and ganglion cell layer. Mü ller cell processes were not stained ( Figure 1 ). There was no immunoreactivity for iNOS, nitrotyrosine, and VEGF.
All diabetic retinas showed strong immunoreactivity for GFAP in nerve fibre layer and ganglion cell layer, which was more pronounced around blood vessels in the innermost retinal layer. Many of these vessels were dilated ( Figure 2 ). Mü ller cell processes that extend Figure 1 Photomicrograph of a retina from a nondiabetic subject that was immunostained for GFAP. Weak GFAP immunoreactivity is confined to the innermost retina in the nerve fibre and ganglion cell layers (arrow). (Original magnification Â 100.) Figure 2 Photomicrograph of a retina from a diabetic subject that was immunostained for GFAP. Note strong GFAP immunoreactivity around dilated retinal vessels in the innermost retina. (Original magnification Â 100.)
iNOS and VEGF are colocalized in diabetic retinas AM Abu El-Asrar et al 308 radially throughout the retina showed moderate GFAP immunoreactivity (Figure 3) .
In all diabetic retinas, cytoplasmic granular immunoreactivity for iNOS was detected in ganglion cells ( Figure 4 ) and in cells in the inner nuclear layer. In addition, cytoplasmic iNOS immunoreactively was observed in GFAP-positive Mü ller cell processes ( Figure  5 ) and in GFAP-positive cells around blood vessels in the innermost retinal layer in serial sections ( Figure 6 ). Strong immunoreactivity for nitrotyrosine was localized to endothelial cells of blood vessels in the innermost retinal layer in six retinas from three subjects (Cases 2, 3, and 4) (Figure 7) . Granular cytoplasmic immunoreactivity for VEGF was observed in ganglion cells and in cells in inner nuclear layer. In addition, numerous cell processes within nerve fibre layer, inner plexiform layer, and inner nuclear layer showed granular cytoplasmic immunoreactivity for VEGF, which was similar to the pattern of cells that stained for GFAP in serial sections (Figure 8) .
In serial sections, ganglion cells and cells in the inner nuclear layer expressing VEGF were localized in the same area of iNOS-expressing ganglion cells and cells in the inner nuclear layer. Control sections did not immunostain, whether we omitted the primary antibody or substituted an irrelevant antibody for the primary antibody.
Discussion
This study showed that, using the procedures described, iNOS, and VEGF have similar distributions and similar immunohistochemical staining patterns with cytoplasmassociated immunoreactivity in ganglion cells, cells in the inner nuclear layer, and glial cells in the retinas from human subjects with diabetes. It has been shown in animal studies that iNOS protein is localized at the ganglion layer, at the inner nuclear layer, and at the outer nuclear layer in the retinas of diabetic rats. 5 iNOS Figure 3 Photomicrograph of a retina from a diabetic subject that was immunostained for GFAP. GFAP immunoreactivity is upregulated in the innermost retina and induced in Mü ller cell processes that extend radially throughout the retina. (Original magnification Â 100.) Figure 4 Photomicrograph of a retina from a diabetic subject that was immunostained for iNOS. Note iNOS immunoreactivity in a ganglion cell (arrow). (Original magnification Â 100.) Figure 5 Photomicrograph of a retina from a diabetic subject that was immunostained for iNOS. Note iNOS immunoreactivity in numerous cell processes (arrow heads). (Original magnification Â 100.)
iNOS and VEGF are colocalized in diabetic retinas AM Abu El-Asrar et al 309 immunoreactivity was observed in the retina in other ischaemic retinopathies as well. Retinal ischaemia induced by common carotid artery occlusion in rats induced iNOS expression in Mü ller cells and retinal ganglion cells. 34 In a murine model of oxygen-induced retinopathy of prematurity, iNOS mRNA was expressed in ischaemic retina. 35 In a previous study we have shown iNOS immunoreactivity in retinal Mü ller glial cells from human patients with diabetes and nonproliferative diabetic retinopathy using immunohistochemistry and heat-induced antigen retrieval with a microwave oven and 30 min incubation with the antibody. 4 In the present study, we used additionally overnight incubation in order to increase antigen retrieval. This resulted in enhanced immunoreactivity without affecting the quality of staining.
In the present study, iNOS and VEGF immunoreactivities were colocalized in ganglion cells and in cells in the inner nuclear layer in serial sections. This colocalization can be explained in two ways, either through a common induction pathway or through a sequential relation in time between both molecules. Ischaemia has been shown to induce the expression of iNOS 34, 35 and VEGF 36 in the ischaemic retina. Yet, other studies demonstrated that VEGF induced the expression of iNOS in human endothelial cells. 23 Recently, several studies demonstrated expression of VEGF receptors in retinal ganglion cells, inner nuclear layer, and Mü ller cells. 37, 38 Induction of iNOS through VEGF stimulates production of NO from rabbit and human endothelial cells through activation of tyrosine kinases and an increase in intracellular calcium. 18, 24, 25 Several studies demonstrated that NO plays a critical role in VEGFinduced vascular hyperpermeability and angiogenesis. In vitro studies showed that VEGF increases Eye permeability 17 and elevates hydraulic conductivity 15 of cultured bovine retinal microvascular endothelial cells through a signalling mechanism that involves NO. In vivo studies demonstrated that an NOS inhibitor blocked VEGF-induced vascular hyperpermeability in all ocular and nonocular tissues. 16 Since the expression of iNOS protein was mainly localized at the level of the retinal vessels, it is possible that the overproduction of NO by the iNOS isoform contributes to blood-retinal barrier breakdown in the retinas of human subjects with diabetes. The mitogenic action of VEGF on endothelial cells is NO mediated since NOS inhibitors block the VEGF-induced proliferation. 19 The experiments of in vivo angiogenesis indicate that NO is downstream imperative of VEGF-induced angiogenesis. Systemic administration of NOS inhibitors to rabbits bearing a corneal implant blocked VEGF-induced angiogenesis. 20 In a rat model of experimental peripheral arterial insufficiency, normal NO production was essential for the enhanced vascular remodelling induced by exogenous VEGF. 39 In a murine model of operatively induced hindlimb ischaemia, impaired angiogenesis in an eNOS knockout mice was not improved by administration of VEGF. 22 Recent evidence indicates that iNOS plays a crucial role in ocular neovascular disease by inducing retinal vaso-obliteration and enhancing pathological intravitreal neovascularization. In a murine model of retinopathy of prematurity, iNOS expression was found to inhibit angiogenesis locally in the avascular retina mediated by a downregulation of VEGF receptor 2, and to encourage intravitreal neovascularization. iNOS inhibitors enhanced angiogenesis in the ischaemic retina and inhibited pathological intravitreal neovascularizaton. In addition, pathological intravitreal neovascularization was significantly reduced in iNOS knockout mice. 35 In addition, Brooks et al 40 demonstrated that oxygeninduced retinal vaso-obliteration was significantly reduced by an NOS inhibitor, strongly supporting a putative role for NO in the retinal vaso-obliterative process. Nitrotyrosine is derived from peroxynitrite, which is formed by the interaction of NO and the superoxide anion radical. Peroxynitrite is implicated in the pathogenesis of neurotoxicity in neurodegenerative diseases 41 and central nervous system inflammation. 42 In a murine model of oxygen-induced retinopathy of prematurity, nitrotyrosine expression occurred in the inner retina early in the course of vaso-obliteration. 40 In the present study, nitrotyrosine immunoreactivity was localized to the vascular endothelium in inner retinal layer consistent with a putative role in the pathogenesis of diabetic microangiopathy. The presence of nitrotyrosine suggests that overexpression of iNOS is associated with NO release in the retinas from human subjects with diabetes.
In the nondiabetic retinas, weak GFAP immunoreactivity was confined to the innermost retinal layers. Mü ller cell processes were not stained. Our observations are consistent with results obtained in human, 43 primate, 44 and rat [30] [31] [32] [33] retinas. Diabetic retinas showed GFAP upregulation in nerve fibre and ganglion cell layers, and GFAP induction in Mü ller cells indicating glial reactivity. Increased GFAP immunoreactivity has also been observed in retinas from diabetic subjects 43 and rats with experimental diabetes. [30] [31] [32] [33] Several studies showed increased GFAP immunoreactivity in early experimental diabetic retinopathy suggesting that glial reactivity is one of the earliest pathological events in the retina during diabetes. [30] [31] [32] [33] The mechanism of the increased GFAP content in the retinas of diabetic subjects is as yet unclear. Rungger-Brändle et al 31 proposed that leakage from the vascular bed not only leads to increased glucose levels within the neural parenchyma capable of inducing glial reactivity by itself but sets free a number of blood-derived factors that are potential additional triggers. As glial cells are implicated in the maintenance of the blood-retinal barrier, 27 our observations of glial reactivity, and expression of iNOS and VEGF by glial cells open the interesting possibility that glial malfunction could contribute to the breakdown of the blood-retinal barrier in diabetic retinopathy. It has been suggested that dysfunction of retinal astrocytes is of importance in ischaemic retinal neovascularization. 45 In conclusion, these findings indicate that iNOS and VEGF are remarkably colocalized in the retinas from human subjects with diabetes. Expression of iNOS with a consequent increase in NO production, together with VEGF, may contribute to the increased blood-retinal barrier permeability and retinal angiogenesis. In addition, activation of glial cells occurs in the retinas from subjects with diabetes and may be involved in the process of tissue damage.
